Abstract. Phosphoinositide-3-OH kinase (PI3K) signalling regulates various cellular processes, including cell survival, growth, proliferation and motility, and is among the most frequently mutated pathways in cancer. Although the involvement of p85α PI3K SH2 domain in signal transduction has been extensively studied, the function of the SH3 domain at the N-terminus remains elusive. A serine (at codon 83) adjacent to the N-terminal SH3 domain in the PI3K regulatory subunit p85α PI3K that is phosphorylated by protein kinase A (PKA) in vivo and in vitro has been identified. Virtually all receptors binding p85α PI3K can cooperate with cAMP-PKA signals via phosphorylation of p85α PI3K Ser83. To analyse the role of p85α PI3K Ser83 in retinoic acid (RA) and cAMP signalling, in MCF7 cells, we used p85α PI3K mutated forms, in which Ser83 has been substituted with alanine (p85A) to prevent phosphorylation or with aspartic acid (p85D) to mimic the phosphorylated residue. We demonstrated that p85α PI3K Ser83 is crucial for the synergistic enhancement of RARα/p85α PI3K binding induced by cAMP/RA co-treatment in MCF7 cells. Growth curves, colorimetric MTT assay and cell cycle analysis demonstrated that phosphorylation of p85α PI3K Ser83 plays an important role in the control of MCF7 cell proliferation and in RA-induced inhibition of proliferation. Wound healing and transwell experiments demonstrated that p85α PI3K Ser83 was also essential both for the control of migratory behaviour and for the reduction of motility induced by RA. This study points to p85α PI3K Ser83 as the physical link between different pathways (cAMP-PKA, RA and FAK), and as an important regulator of MCF7 cell proliferation and migration.
Introduction
The phosphoinositide-3-OH kinase (PI3K) family of lipid kinases regulates cell survival and growth, as well as migration (1) . This signalling pathway is deregulated in most human cancers by differential gene expression, amplification or mutation (2) (3) (4) (5) . Most of p85α PI3K mutations cluster in the inter-SH2 (iSH2) domain of the molecule (5, 6) , which interacts with the catalytic subunit p110α PI3K (7, 8) . A serine (at codon 83) was identified adjacent to N-terminus SH3 domain in the PI3K regulatory subunit p85α PI3K , that is critical for cell cycle progression and cell survival in normal epithelium (9) . p85α PI3K Ser83 is phosphorylated by protein kinase A (PKA) in vivo and in vitro, influencing the ability of SH3 domain to interact with different partners (10, 11) . Nearly all receptors binding p85α PI3K can cooperate with cAMP-PKA signals via phosphorylation of p85α PI3K Ser83, thus explaining the pleiotropic nature of the effects exerted by cAMP-PKA on several, apparently unrelated, signalling cascades.
In many steroid-dependent cancers, a close cross-talk exists between growth factor and steroid signalling which thus converge in the PI3K/AKT pathway; this signalling cascade is frequently deregulated in breast cancer (12) . All-trans retinoic acid (RA) is a vitamin A derivative involved in the growth inhibition of breast cancer cell lines (13) (14) (15) (16) (17) (18) (19) . It has been demonstrated that administration of RA resulted in activation of PI3K signalling through a mechanism in which a stable complex including retinoic acid receptor α (RARα) and p85α PI3K occurs also in the absence of RA (20, 21) . It has also been described that the PI3K binding to estrogen receptor and PKA RIIβ subunit, is finely regulated by the PKA-induced phosphorylation of the p85α PI3K Ser83 (9, 10) . Since p85α PI3K binds several types of receptors and adaptors, the phosphorylation of Ser83 by PKA can induce a conformational change of the PI3K complex, which results in facilitated binding to these partners, thereby modulating PI3K activity (9, 10) . This site represents probably a nodal point, where information from several receptors, that regulate cell growth, survival, adhesion and motility, is channelled to PI3K.
The aim of this work was to analyse the role of the SH3 domain of p85α PI3K in RA and cAMP-PKA signalling, using as model the breast cancer cell line MCF7, which expresses functional RARα receptor. For this purpose, we tested whether p85α PI3K Ser83 modulates the binding of RARα to PI3K after treatment of MCF7 cells with RA and cAMP. Furthermore, we analysed the biological consequences of the expression of mutant versions of p85α PI3K in MCF7 cells, focusing on the role of p85α PI3K Ser83 in cell motility, growth and survival.
Materials and methods
Cell cultures and plasmid transfection. MCF7 cells were obtained from American Type Culture Collection (ATCC, Rockville, MD, USA) and cultured as previously described (9) . All experiments were performed in quiescent cells growing for 48 h in phenol red-free DMEM (Lonza; Verviers, Belgium) and 5% charcoal-stripped serum (Biowest; Nuaillé, France). All-trans retinoic acid, 8-Br-cAMP and H89 were from SigmaAldrich Co. (St. Louis, MO, USA). Plasmids carrying bovine p85α PI3K wt tagged with FLAG (pSG5-FLAG-p85wt), or its Ser83 mutated forms, p85A (pSG5-FLAG-p85A) and p85D (pSG5-FLAG-p85D) were obtained as previously described (9) . pSG5-RARα plasmid was kindly provided by Prof. Domingo Barettino, Instituto de Biomedicina de Valencia. Transfections were performed using Lipofectamine Plus, Gibco BRL, Life Technologies (Rockville, MD, USA) following the manufacturer's instructions. In all transfections, pEGFPC3 plasmid was included to determine and normalize transfection efficiency. Experiments varying in the transfection efficiency >20% were discarded.
Western blotting and immunoprecipitation. Lysates from transfected MCF7 cells were separated by SDS-PAGE and immunoblotted as previously described (10) . Antibodies against RARα and β-actin were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Antibodies against p85α PI3K and phosphorylated FAK were from Upstate Biotechnology, Inc. (Lake Placid, NY, USA). Antibody against FlagM2 was from Sigma-Aldrich Co. For immuno precipitation, cell lysates (1 mg) were incubated with 8 µg of antibodies against anti-FlagM2 or RARα, or with 5 µl of antibody against p85α PI3K ; immunocomplexes were precipitated using anti-rabbit IgG beads ExactaCruzF, from Santa Cruz Biotechnology, Inc., following the manufacturer's instructions, and processed for western blot analysis as described.
Clonogenic assays. MCF7 cells (3x10 2 ) expressing p85α PI3K wt or its mutants were seeded into 6-well plates that were then incubated at 37˚C for ~10 days until cells have formed sufficiently large clones (at least 50 cells). Clones were counted after 30 min fixing with a mixture of 6% glutaraldehyde and 0.5% crystal violet.
Cell growth analysis. Proliferation was assessed by cell counting and by MTT assays using the 3-(4,5-dimethylthiazol-2-yl)-2,5-biphenyltetrazolium bromide (MTT) (Sigma-Aldrich Co.) as previously described (10) .
Cell cycle analysis. Cell cycle analysis was performed by Fluorescence-activated cell sorting (FACS) as described (10) . Fluorescence was determined by using the FACScan flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA).
Wound healing assays. Confluent MCF7 cells were scratched with a p200 pipette tip, and cellular debris was removed by washing gently. Following wounding, culture medium was replaced with fresh medium and cells were exposed to RA 30 µM for 16 h. Images were acquired on a phase contrast microscope Axio Observer (Carl Zeiss, Inc., Oberkochen, Germany) and wound diameter was measured at 0 and 16 h using the computing software Axio Vision (Carl Zeiss, Inc.).
Migration assays. Cell migration was measured using a Transwell migration chamber (diameter 5-mm, pore size 8 µm; Costar Corporation, Cambridge, MA). Cells grown to 70% confluence in Petri tissue culture dishes were detached using EGTA 1X (Sigma-Aldrich Co.) and resuspended in serum-free medium containing 0.2% BSA. RA (30 µM) treated and untreated cells (30x10 5 cells/100 µl) were seeded in the upper compartment of transwell and allowed to migrate trough the polycarbonate filters coated with Fibronectin (40 µg/ml in serum-free medium containing 0.2% BSA). The lower compartment was filled with phenol red-free DMEM with 10% charcoal-stripped serum. After 1, 2 or 4 h of incubation at 37˚C, relative numbers of cells transmigrated through the membrane were determined by staining cells on the undersurface of the Transwell membrane with Crystal Violet followed by cell lysis and measurement of absorbance values at 540 nm.
Statistical analyses. All data are presented as the means ± SE of at least three experiments in triplicates (n≥9). Statistical significance between groups was determined using Student's t-test (matched pairs test or unmatched test as appropriate). All statistical analyses were performed using JMP Software (Statistical Discovery SAS Institute). P<0.05, statistical significance; P<0.001, high statistical significance.
Results

RARα and p85α
PI3K interactions. In order to study whether p85α interacted with RARα, immunoprecipitation experiments were performed in MCF7 cells made quiescent by charcoal-treated serum and medium lacking phenol-red for 48 h, and treated with RA 10 µM and/or cAMP 200 µM, and/or the PKA inhibitor, H89 10 µM, or their vehicles for 30 min. Immunoprecipitation of total cell lysates with anti-RARα antibody, showed a physical association between p85α PI3K and RARα in all conditions examined (Fig. 1A, upper panel) . In particular, RA treatment increased 4-fold the formation of p85α PI3K /RARα complex, while cAMP stimulation showed 2.5-fold increase, with respect to untreated cells. Of note, the co-treatment with RA and cAMP induced a significant and synergistic enhancement of the binding (9-fold, P<0.001). Treatment of MCF7 cells with H89, did not modify the basal interaction, but abolished synergy with cAMP. Western blot on total lysates showed that RA treatment induced downregulation of RARα protein, as already reported by Bastien et al (22) . p85α PI3K and β-actin expressions in inputs were shown (Fig. 1A , lower panel). These findings collectively established that endogenous RARα and p85α PI3K interact in MCF7 cells also in absence of RA, and that the co-treatment with RA and cAMP-PKA is required for the synergistic enhancement of this binding.
It has been previously identified that Ser83 in the p85α PI3K molecule is phosphorylated in vivo and in vitro by PKA (23) .
To determine the relevance of this phosphorylation in the formation of the complex RARα/p85α PI3K , it has been substituted Ser83 with alanine (p85A) to prevent phosphorylation or with aspartic acid (p85D) to mimic the phosphorylated residue (9, 10) . Immunoprecipitation experiments were performed in quiescent MCF7 cells transiently transfected with a construct containing p85α PI3K wt or its Ser83 mutated forms. In order to minimize the negative regulation of PI3K signalling, caused by p85α PI3K overexpression (24), we used only lysates from cells with comparable transfection efficiency (>70%). Immunoprecipitation experiments with anti-FLAG antibody demonstrated that overexpression of the mutated forms of p85α PI3K , significantly (P<0.001) impairs the interaction between RARα and p85α PI3K (Fig. 1C) . Histograms, in Fig. 1B  and D , represent the ratio of p85α PI3K /RARα densitometric bands in the RARα immunoprecipitates, and the ratio of RARα/FLAG densitometric bands in the FLAG-p85α PI3K immunoprecipitates, respectively, derived from three independent experiments performed in triplicate. Fig. 2A and B) . Cells overexpressing p85α PI3K mutants, although maintained the ability to form the p85α PI3K /RARα complex in all conditions examined, showed a significant (P<0.001) reduction of the synergistic effect of cAMP/ RA treatment with respect to cells overexpressing p85α PI3K wt. Moreover, the reduction of p85α PI3K /RARα binding observed after H89 treatment in the cells overexpressing p85α PI3K wt, was completely abolished in both p85α PI3K mutant transfected cells. Taken together, these data demonstrated that p85α PI3K Ser83 is crucial for the synergistic enhancement of RARα/p85α PI3K binding induced by cAMP/RA.
Cell growth effects of p85α
PI3K Ser83 phosphorylation. PI3K-AKT is one of the most important pathways promoting survival and cell growth (25) . In order to study whether the impairment of the RARα/p85α PI3K binding modified the biological behaviour of MCF7 cells overexpressing the mutated forms of p85α PI3K , we performed clonogenic and proliferation assays.
The overall survival of MCF7 cells transfected with the p85α PI3K mutants, was evaluated by clonogenic assays in basal condition or after treatment with H89 10 µM. As shown in Fig. 3 , overexpression of p85A induced a statistically significant PI3K showed an inhibition of cell proliferation at each time period examined. This effect was probably due to the overexpression of p85α PI3K in the cells, that acts as a negative regulator of PI3K signalling and a potential tumour suppressor (23) . Furthermore, the growth rate observed in cells overexpressing p85A was significant lower (P<0.05) with respect to that observed in cells overexpressing p85α PI3K wt or D (Fig. 4A) . Trypan blue test performed in all proliferation assays demonstrated that the growth inhibition was not due to reduction of cellular viability (data not shown). Similar results were obtained by colorimetric MTT assay (Fig. 4B) . FACS analysis confirmed that only cells expressing p85A showed a lower proliferation rate, as demonstrated by a significant (P<0.001) reduction of the percentage of cells accumulated in G2 (Fig. 4C ). Collectively these results demonstrated that phosphorylation of p85α PI3K Ser83 plays an important role in the control of MCF7 cell proliferation.
The cell growth rate was also analysed in cells over expressing p85α PI3K mutants, untreated or treated with RA 30 µM, cAMP 200 µM or both of them for 12, 48 and 72 h. Our results demonstrated a consistent inhibition of cell replication in the cells that had undergone RA and/or cAMP treatment (Fig. 5A) . In particular, a significant (P<0.001) reduction of proliferation was observed in MCF7 cells overexpressing p85α PI3K wt or empty vector after 48 h of RA treatment, while cells overexpressing p85A or D, showed only a small inhibition of growth. Whereas cAMP treatment induced a significant (P<0.001) inhibition of proliferation in all conditions examined, co-treatment with RA and cAMP induced a significant (P<0.001) and synergistic inhibition of growth in cells overexpressing p85α PI3K wt, D or empty vector, but not in those overexpressing p85A (Fig. 5B) . These different behaviours could be a consequence of the decreased RARα/p85α PI3K binding (Fig. 1B) . Taken together these results indicated that Ser83 was involved in RA-induced inhibition of MCF7 cell proliferation, and that phosphorylation of this residue is required for the cAMP/RA synergistic inhibition of growth.
Role of phosphorylation of p85α
PI3K Ser83 in the control of migratory behaviour. PI3K has multiple roles in cell migration in many cell types and systems, acting redundantly with multiple other pathways to co-ordinate polarity (1) . Moreover RA and other biologically active retinoids inhibit cellular migration in Airway SMCs (26) and in different breast cancer cell lines (27, 28) .
The role of phosphorylation of p85α PI3K Ser83 in MCF7 cell migration, was investigated performing wound healing assays in presence or not of RA. Our results demonstrated that expression of p85A had an effect per se on MCF7 migration, displaying a statistically significant (P<0.001) reduction of migration (89% vs. empty vector, 84% vs. p85α PI3K wt and 88% vs. p85D). RA treatment induced a significant (P<0.05) reduction of migration in cells overexpressing p85α PI3K wt or empty vector, while it did not inhibit the motility in cells overexpressing p85D. The responsiveness to RA administration was not detectable in cells overexpressing p85A, because of their inability to migrate (Fig. 6) . Similar results were obtained by Transwell experiments performed onto fibronectin-coated surfaces in presence or not of RA (Fig. 7A and B) . Our data demonstrated that p85α PI3K Ser83 was essential both for the control of migratory behaviour and for the reduction of motility induced by RA.
It has been demonstrated that p85α PI3K interacts with focal adhesion kinase (FAK), a cytoplasmic tyrosine kinase involved in integrin-mediated signal transduction pathways (29) . FAK influences both focal adhesion assembly and disassembly, and is required for the dynamic regulation of integrin focal adhesions 
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during cell migration (30) . In order to clarify whether FAK was involved in the control of migratory behaviour mediated by p85α PI3K , lysates from MCF7 cells transiently transfected with p85α PI3K wt or p85A or p85D and treated with 30 µM RA for 10 min, were immunoprecipitated with anti-FLAG antibody and then sequentially analysed by western blotting with anti-P-FAK (Y397), anti-RARα and anti-p85α PI3K antibodies. Our results demonstrated for the first time that p85α PI3K , P-FAK and RARα co-immunoprecipitated; in particular, the complex formation was strongly enhanced in cells expressing p85A and reduced in those expressing p85D (Fig. 8) . RA treatment strongly increased the formation of RARα/PI3K/P-FAK complex in all conditions examined. These results indicate that phosphorylation of p85α PI3K Ser83 plays an important role in the formation of the PI3K/P-FAK complex, and in the modulation of this binding mediated by RA.
Discussion
The data presented herein indicated that p85α PI3K Ser83 and the near SH3 domain represent a nodal point modulating information from several signalling cascades converging on PI3K, such as RA and cAMP pathways. Several studies demonstrated that members of the superfamily of nuclear receptors, such as estrogen receptors (ER) (31) (32) (33) and thyroid receptors (34), interact with p85α PI3K and activate the PI3K/ AKT pathway. A stable physical interaction between RARα and p85α PI3K has been demonstrated in different cell lines (20, 35) . p85α PI3K Ser83 represents the physical link between Ras, ER and cAMP-PKA, since its phosphorylation stimulates both the activity of PI3K and its binding to ER and PKA RIIβ subunit (9, 10) . Recent studies demonstrated that Ser83 binding to 14-3-3ζ protein, facilitates the interaction of PI3K with other adapter molecules, enhancing its activity and p85α PI3K membrane localization (11) .
Nearly, all receptors binding p85α PI3K can cooperate with cAMP-PKA signals via phosphorylation of p85α PI3K Ser83, thus explaining the pleiotropic nature of the effects exerted by cAMP-PKA on several, apparently unrelated, signalling cascades (9) . This study demonstrates that RARα interaction with p85α PI3K depends on the presence of p85α PI3K Ser83, and this residue plays an important role in the fine regulation of the binding induced by cAMP-PKA. The ability of the cAMP/PKA signalling to synergize with RA has been shown in different cellular models (36) (37) (38) . Our results demonstrate that the co-treatment of MCF7 cells with RA and cAMP amplifies synergistically the RARα/ p85α PI3K binding, and that the presence of p85α PI3K Ser83 is crucial for the maintenance of this synergy.
Recent studies highlighted the importance of p85α PI3K Ser83 in the control of cell growth in different cellular models, such as FRTL-5 (10), NIH3T3 cells (9) and vascular SMCs (39), but it is worth noting that the same phosphorylation leads to opposing phenotypes, depending on the cell type. In fact the phosphorylation of p85α PI3K Ser83 inhibits cell proliferation in fibroblasts and VSMC, while it is essential for the correct cell cycle progression in thyroid cells, and does not affect cell proliferation of endothelial cells (9, 10, 39) . Our results show that phosphorylation of p85α PI3K Ser83 is essential for MCF7 cell survival and proliferation, as demonstrated by the low growth rate observed in cells overexpressing the p85A mutant. Ser83 seems to play a role in mediating the growth inhibitory effects of RA. Retinoic acids, including vitamin A and its analogues, regulate growth and differentiation; they suppress tumour formation in animals and have shown to be effective chemotherapeutic agents in many cancers (26) . The antitumour effect of retinoids is most often attributed to the induction of differentiation, but these compounds were also shown to arrest the growth of tumour cells (40) . Many groups have found that retinoids potently inhibit the growth of breast cancer cell lines (15, 16) . In our model, we demonstrate that the expression of p85α PI3K mutated forms in MCF7 cells is responsible of a robust reduction of growth inhibition induced by RA treatment, due to a significant reduction of the RARα/ p85α PI3K complex formation. Another important mediator of proliferation is cAMP, which regulates cell proliferation in different manner depending on cell type (41) . cAMP induces proliferation in FRTL5 thyroid cell (42, 43) , while it inhibits proliferation in NIH 3T3 (44) . A differential regulation of VSM and endothelial cell proliferation, by cAMP/PKA-activated p85α PI3K has also been described (39) . In our model cAMP treatment is able to reduce cell proliferation in all conditions examined. Therefore, we believe that Ser83 is not essential to mediate the inhibitory effects of cAMP, since it can also inhibit cell proliferation in a PKA-independent manner (45) . Nevertheless, we demonstrate that phosphorylation of p85α PI3K Ser83 is required for the cAMP/RA synergistic inhibition of growth.
PI3K isoforms have multiple roles in cell migration in many cell types and systems, but the relative contribution of PI3Ks to different steps of migration depends on the cell state and the combinations of stimuli to which it is exposed (1). Direct PI3K activation is sufficient to induce cell motility and invasion (46) . To date, the role of p85α PI3K Ser83 in the migratory behaviour of cells has not yet been reported. This study demonstrates that the overexpression of p85A induces a highly significant suppression of MCF7 cells motility, indicating that the phosphorylation of p85α PI3K Ser83 is a critical regulator of this process. Moreover, our data demonstrate that RA treatment causes a significant reduction of motility only in cells expressing p85α PI3K wt, underlying that p85α PI3K Ser83 is essential also for RA-induced inhibition of migration. Numerous studies indicate FAK as an important player in signalling cascades associated with cancer progression and metastasis (47) . Moreover, FAK phosphorylation has been demonstrated in different tumour cell types (48) (49) (50) , and several studies reported that p85α PI3K interacts with FAK (29, 33) . Our data clearly demonstrate the existence of a ternary complex p85α
PI3K /RARα/P-FAK in which P-FAK Y397 Figure 8 . Effect of the substitution of p85α PI3K Ser83 on the formation of P-FAK/PI3K complex. MCF7 cells, transiently transfected with p85α PI3K wt, p85A or p85D, were treated with 30 µM RA for 10 min. Total lysates were normalized for transfection efficiency and then immunoprecipitated with FLAG antibody. After western blotting the filter was sequentially developed with anti-p85α PI3K , anti-P-FAK (Y397) and anti-RARα antibodies, using horseradish peroxidase-conjugated Rabbit ExactaCruzF as secondary antibody. The histogram represents the ratio of P-FAK/p85α PI3K densitometric bands in the p85α PI3K immunoprecipitates, derived from three independent experiments. participation is strongly enhanced in cells overexpressing p85A and reduced in those overexpressing p85D. We believe that these differences in the ability to bind P-FAK displayed by the p85α PI3K mutants, may be responsible for the different migratory behaviour observed in our experiments. Although increased FAK expression has been correlated with increased cell motility, invasiveness and proliferation (16, (51) (52) , it has been widely demonstrated that the activation of FAK/PI3K/ Rac1 signalling inhibits MCF7 cell motility, reflecting differential activation of FAK via phosphorylation of additional sites (53) (54) (55) . However, phosphorylation of FAK Tyr397 has been found correlated to inhibited cell migration in a human breast cancer cell line (56) , and in squamous cancer cell lines (57) . We think that the inhibition of migration observed in MCF7 cells after RA treatment, could be due to the enhanced formation of p85α PI3K /RAR/P-FAK Y397 complexes induced by RA. Further investigations are required to understand the discrepancy observed in MCF7 cells overexpressing p85D mutant, where RA treatment induces the P-FAK/p85α PI3K complex formation, but is not able to inhibit migration.
This study provides evidence of the existence of a complex RARα/PI3K/P-FAK in MCF7 cells, that is fine-regulated by phosphorylation of p85α PI3K Ser83 and RA treatment. Changes in binding affinity of this complex are responsible for cell migration impairment. The data presented above have broad implications since they point to p85α PI3K Ser83 as the physical link between different pathways (cAMP-PKA, RA and FAK), and as an important regulator of MCF7 cell proliferation and migration.
Further work will be necessary to determine the mechanisms by which Ser83 interacts with other pathways in order to evaluate the clinical implication of these findings.
